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Background: 
The analgesic mechanisms of cyclooxygenase (COX)-2 inhibitors have been explained mainly on the basis 
of the inhibition of prostaglandin biosynthesis. However, several lines of evidence suggest that their analgesic 
effects are mediated through serotonergic or adrenergic transmissions. We investigated the roles of these 
neurotransmitters in the antinociception of a selective COX-2 inhibitor at the spinal level.
Methods: 
DUP-697, a selective COX-2 inhibitor, was delivered through an intrathecal catheter to male Sprague-Dawley 
rats to examine its effect on the flinching responses evoked by formalin injection into the hindpaw. 
Subsequently, the effects of intrathecal pretreatment with dihydroergocristine, prazosin, and yohimbine, which 
are serotonergic, α1 adrenergic and α2 adrenergic receptor antagonists, respectively, on the analgesia induced 
by DUP-697 were assessed.
Results: 
Intrathecal DUP-697 reduced the flinching response evoked by formalin injection during phase 1 and 2. But, 
intrathecal dihydroergocristine, prazosin, and yohimbine had little effect on the antinociception of intrathecal 
DUP-697 during both phases of the formalin test. 
Conclusions: 
Intrathecal DUP-697, a selective COX-2 inhibitor, effectively relieved inflammatory pain in rats. Either the 
serotonergic or adrenergic transmissions might not be involved in the analgesic activity of COX-2 inhibitors 
at the spinal level. (Korean  J  Pain  2011;  24:  179-184)
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Table 1. Pharmacological Characteristics of the Experimental Drugs
Drug & chemical name
Subtype affinity 
(pA2)*
Elimination 
half-life (hour)
Dose 
(μg)
Dihydroergocristine:
(5'α,10α)-9,10-Dihydro-12'-hydroxy-2'-(1-methylethyl)-
5'-(phenylmethyl)-ergotaman-3',6',18-trione mesylate
Non-selective 5-HT receptor antogonist 13.6 3
α1
(vs noradrenalin)
α2
(vs clonidine)
α2/α1
†
Prazosin:
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-
(2-furanylcarbonyl)piperazine hydrochloride
8.18 ± 0.11 5.94 ± 0.10 0.006  1.9 3
Yohimbine:
17α-Hydroxyyohimban-16α-carboxylic 
acid methyl ester hydrochloride
6.49 ± 0.06 8.14 ± 0.05 45  7.7 10
Data are expressed as mean ± SEM. *Log[concentration of antagonist which necessitates doubling the concentration of agonist]
−1,
†Calculated from the antilogarithm of the difference between the pA2 values obtained at α2 and α1 adrenergic receptors.
INTRODUCTION
    Cyclooxygenase (CO X)-2 inhibitors are one of the 
most  commonly  used  types  of  analgesics.  Inhibition  of 
COX-2, which is increased in the spinal cord after periph-
e r a l  i n f l a m m a t i o n  [ 1 ] ,  a n d  t h e  c o n s e q u e n t  b l o c k a d e  o f  
prostaglandin biosynthesis, have been widely accepted as 
the  mechanisms  underlying  the  analgesic  action  of  this 
group of drugs. However, several lines of evidence suggest 
that their analgesic effects are also exerted by a variety 
of  peripheral  and  central  mechanisms  including  endo-
cannabinoids, nitric oxide, and the monoaminergic, chol-
inergic, and opioid systems [2,3]. 
    Among them, monoamines such as serotonin (5-hydro-
xytryptamine, 5-HT) and norepinephrine (NE), and their 
corresponding receptors, were shown to be present within 
the spinal cord [4,5] and to play an important role in the 
modulation of nociceptive transmission [6]. The involve-
m e n t  o f  5 - H T  a n d  N E i n t h e a n t i n oc i c e p t i v e  e f f ec t s  o f 
CO X-2 inhibitors has already been documented in other 
reports with animal models. Orally administered rofecoxib 
increased 5-HT levels in the rat frontal cortex, and the 
analgesic activity of this COX-2 inhibitor was significantly 
decreased by depletion of central 5-HT [7]. Additionally, 
destruction of bulbospinal noradrenergic projection neurons 
by intracerebroventricular injection of 6-hydroxydopamine 
was shown to eliminate the effect of nonsteroidal anti-in-
flammatory drugs [8]. Taken together, these data indicate 
that there is an interaction of COX-2 inhibitors with the 
central serotonergic and adrenergic systems. However, at 
the spinal level, these interactions are not clearly defined.
    The aim of this study was to clarify the roles of 5-HT 
and NE on the analgesic activity of COX-2 inhibitors at 
the spinal level. Therefore, 5-HT receptor antagonists and 
α1 adrenergic and α2 adrenergic receptor antagonists were 
intrathecally administered to investigate their ability to re-
verse the antinociception produced by COX-2 inhibitors in 
a rat model of inflammatory pain.
MATERIALS  AND  METHODS
    All procedures were carried out with the approval of 
the Institutional Animal Care Committee, Research Insti-
tute of Medical Science. Male Sprague-Dawley rats weigh-
ing 250-300 g were used in these experiments. The rats 
were housed in a vivarium maintained at 20-23
oC with a 
12 h light/dark cycle, and were given food and water ad 
libitum. A polyethylene tube (PE-10) was catheterized and 
i n s e r t e d  i n t o  t h e  s u b a r a c h n o i d  s p a c e  i n  s e v o f l u r a n e -  
anesthetized rats as described previously [9,10]. The rats 
were closely  monitored  and,  if motor abnormalities ap-
peared, they were euthanized through a volatile anesthetic 
overdose. Normal rats were kept in individual cages, and 
a period of not less than 5 days was allowed for each rat 
to recover from intrathecal catheterization. Rats displaying 
apparently normal behavior and weight gain were then as-
signed to the experiment.
    The f ollowing drugs were used in this study: DUP-697 HJ Jeong, et al / COX-2 Inhibitor and Monoamine 181
Fig. 1. Time course (A) and dose-response curves of intrathecal DUP−697 on flinching response during phase 1 (B) and 
phase 2 (C) in the formalin test. DUP−697 was administered 10 min before the formalin injection. Data are presented
as the number of flinches or the percentage of control. Each line represents mean ± SEM of 7 rats. Compared with control, 
*P ＜ 0.05, 
†P  ＜ 0.005, 
‡P  ＜ 0.001.
(5-Bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phe-
nyl]-thiophene),  dihydroergocristine  mesylate  (Research 
Biochemical Internationals, Natick, MA, USA), and prazosin 
hydrochloride and yohimbine hydrochloride (Sigma Aldrich 
Co., St. Louis, MO, USA). All drugs were dissolved in 100% 
d i m e t h y l s u l f o x i d e  ( D M S O )  a n d  i n t r a t h e c a l l y  a d m i n i s t e r e d  
using a hand-driv en, gear-operated syringe pum p. The 
drugs were delivered in a volume of 10 μl solution, followed 
by an additional 10  μl of saline to flush the catheter.
    On experiment days, the rats were placed in a re-
straining cylinder and held for 20 min for adaptation. T o 
investigate the effect of COX-2 inhibitor in the formalin 
test,  rats  were  treated  intrathecally  with  vehicle  or 
DUP-697 (10, 30, 100, 300 μg), administered 10 min before 
the formalin test (n = 7 in each group). Doses of DUP-697 
were determined based on previous studies [2]. Next, rats 
were pretreated with dihydroergocristine (5-HT receptor 
antagonist, 3 μg), prazosin (α1 adrenergic receptor antag-
onist, 3 μg), or yohimbine (α2 adrenergic receptor antago-
nist, 10 μg), in order to determine the roles of these agents 
in the activity of DUP-697 (n = 7 in each group). Pharma-
c o l o g i c a l  c h a r a c t e r i s t i c s  o f  t h e s e  a n t a g o n i s t s  a r e  p r e -
sented in Table 1 [11-15]. Doses of the drugs were chosen 
based  on  previous  experiments,  in  which  the  maximum 
dosage that did not affect the control formalin response 
or cause side effects such as motor impairment was de-182 Korean J Pain Vol. 24, No. 4, 2011
Fig. 2. The effects of intrathecal dihydroergocristine (3 μg), prazosin (3 μg), and yohimbine (10 μg) on the antinociception
of intrathecal DUP−697 (300 μg) during phase 1 (A) and phase 2 (B) in the formalin test. Dihydroergocristine, prazosin, 
and yohimbine were administered 10 min before the delivery of DUP−697, and the formalin test was done 10 min later.
None of these antagonists affected the antinociception of DUP−697 during both phases of the formalin test. Data are
presented as the percentage of control. Each bar represents mean ± SEM of 7 rats.
t e r m i n e d  [ 1 6 ] ,  a n d  t h e  d r u g s  w e r e  a d m i n i s t e r e d  i n t r a -
thecally 10 min before the delivery of intrathecal DUP-697 
(300 μg). The formalin test was performed 10 min later.
    F or the formalin test, 50 μl of 5% formalin was in-
jected subcutaneously into the plantar surface of the rat 
hindpaw. The number of flinches was counted for 1-min 
periods at 1 and 5 min after the formalin injection, and 
every 5 min thereafter. Rats were observed for a total pe-
r i o d  o f  6 0  m i n .  O b s e r v e d  r e s p o n s e s  w e r e  d i v i d e d  i n t o  
phase 1 (0-9 min) and phase 2 (10-60 min) of the formalin 
test. The researcher who tested the drugs was blind to the 
drug given to each animal. Data are expressed as mean 
± SEM. Time-response data or dose-response data are 
shown either as the number of flinches or the percentage 
of control in the two phases. The control study was done 
with 100% DMSO, and the flinching number of the ex-
perimental group was converted to a percentage of control 
as follows:
% of control = 
Total flinching number with drug in phase 1 (2)
× 100%
Total flinching number of control in phase 1 (2)
    Dose-response data was analyzed using the Kruskal- 
Wallis test and the Mann-Whitney U test. Comparison of 
antagonism for the effect of DUP-697 was analyzed by 
Mann-Whitney U test. A P value ＜ 0.05 was considered 
statistically significant.
RESULTS
    Subcutaneous injection of formalin into the paw pro-
duced a biphasic flinching response, with an early (phase 1) 
response lasting 5-10 min, and after a quiescent interval 
of 5-10 min, a subsequent late (phase 2) response lasting 
up to 60 min. Fig. 1A shows the time course and dose-re-
sponse data of intrathecal DUP-697, administered 10 min 
before formalin injection, for the formalin test. In the con-
trol group with intrathecal injection of DMSO, total flinch-
ing number was 29 ± 3 during phase 1 and 217 ± 6 during 
phase 2. In rats with intrathecal administration of DUP- 
697, total flinching number was decreased to 33-52% and 
42-77%  of  the  control  group  during  phases  1  and  2, 
respectively.  Fig.  1B  and  1C  show  the  dose-response 
curves of intrathecal DUP-697 on flinching response dur-
i n g  p h a s e s  1  a n d  2  o f  t h e  f o r m a l i n  t e s t .  I n t r a t h e c a l  
DUP-697 reduced the flinching response in a dose-de-
pendent manner during both phases of the formalin test.
    The percentage of control of DUP-697 300 μg was 
33% and 42% during phases 1 and 2, respectively. When 
rats were pretreated intrathecally with dihydroergocristine 
10 min before DUP-697 administration, the percentage of 
control  during  phases  1  and  2  was  41%  and  34%,  re-
spectively (P ＞ 0.05, Fig. 2). The percentage of control HJ Jeong, et al / COX-2 Inhibitor and Monoamine 183
of the prazosin-pretreated group during phases 1 and 2 
was 30% and 40%, respectively (P ＞ 0.05, Fig. 2), and 
that of the yohimbine-pretreated group was 32% and 40%, 
respectively (P ＞ 0.05, Fig. 2). Therefore, intrathecal pre-
treatment  with  dihydroergocristine,  prazosin,  and  yo-
himbine did not reverse the flinching response during both 
phases of the formalin test. There was no apparent abnor-
mal behavior in the rats following the administration of the 
experimental drugs.
DISCUSSION
    F ormalin-induced nociception consists of two diff erent 
nociceptive states. The first is acute nociception (phase 1), 
which is followed by the facilitated state (phase 2). The 
phase 1 response appears to result from an immediate and 
intense increase in the primary afferent activity. On the 
other hand, the phase 2 response mirrors the activation 
of wide dynamic range neurons of dorsal horn with a con-
t i n u o u s  l o w  l e v e l  o f  a c t i v i t y  i n  t h e  p r i m a r y  a f f e r e n t .  
Therefore, phase 2 reflects a facilitated state which ap-
pears to be a prominent and intensified state of pain in 
spite of a reduced level of afferent input [17]. This pain 
model may serve as a tool for observing the effects of var-
ious analgesic agents on these two pain types at once. 
    In this study, intrathecal DUP-697 reduced the flinch-
ing  response  evoked  by  formalin  injection  during  both 
phases of nociception, indicating that this selective COX-2 
inhibitor possesses a central mechanism of action at the 
s p i n a l  l e v e l ,  a  f i n d i n g  c o n s i s t e n t  w i t h  p r e v i o u s  r e p o r t s  
[2,18]. On the other hand, pretreatment with 5-HT re-
ceptor and α1 and α2 adrenergic receptor antagonists did 
not  antagonize  the  effect  of  intrathecally  administered 
D U P - 6 9 7 .  T h e s e  f i n d i n g s  s u g g e s t  t h a t  t h e  a n a l g e s i c  
mechanisms of COX-2 inhibitor might not be associated 
with either the serotonergic or adrenergic systems, at least 
in the spinal cord. 
    Nevertheless, as documented earlier, previous reports 
support the involvement of central monoaminergic trans-
missions in the antinociceptive activity of COX inhibiting 
agents [7,8,19-22]. The discrepancy between our data and 
these previous reports may result from methodological dif-
ferences in the experiments, such as the types of stimuli 
utilized, the types and doses of drugs administered, the 
relative affinities or selectivities of the drugs used, and the 
routes of drug delivery. However, several reports support 
our results in terms of the routes of drug delivery. Intra-
p e r i t o n e a l l y  a d m i n i s t e r e d  a c e t y l s a l i c y l i c  a c i d  a n d  a c e t -
aminophen significantly increased 5-HT and NE content in 
the brain [19-21], but such an elevation was not observed 
in the spinal cord [21]. In addition, the antinociceptive ef-
fect of orally administered paracetamol was reversed by a 
5-HT1A receptor antagonist [22]. However, when the same 
drug was delivered intrathecally, a 5-HT1A receptor antag-
onist did not inhibit its analgesic action [22]. An agent ad-
ministered  systemically  can  reach  supraspinal  sites  to 
stimulate  descending  serotonergic  pathways,  which  may 
p a r t i c i p a t e  i n  t h e  a n t i n o c i c e p t i o n  p r o d u c e d  b y  i n t r a -
peritoneally or orally administered COX inhibiting agents. 
On the other hand, intrathecal delivery in the volume used 
in the current study (20 μL) may not spread more proximally 
than the basal cistern and would be confined to the spinal 
cord [23,24]. Therefore, the analgesic action induced by 
i n t r a t h e c a l  i n j e c t i o n  o f  C O X - 2  i n h i b i t o r  i n  t h e  c u r r e n t  
study might have not activated serotonergic pathways.
    Systemic administration of adrenergic receptor ago-
nists with diclofenac or ketoprofen resulted in a synergistic 
antinociceptive  effect,  while  intrathecal  combinations  of 
the same drugs exhibited an additive rather than syner-
gistic interaction [25,26]. Similarly, systemic, but not in-
trathecal, coadministration of metamizol, nimesulide, ace-
taminophen, piroxicam or naproxen with clonidine showed 
supraadditivity [27]. These data indicate that COX inhibit-
ing agents may activate supraspinal mechanisms to inter-
act with the noradrenergic system. Taken together with the 
results of the current investigation, these findings suggest 
that the antinociceptive effects of COX-2 inhibitors might 
involve not spinal but instead mainly supraspinal mono-
aminergic transmissions.
    There are some limitations to the current study. First, 
we evaluated the roles of 5-HT and α1 and α2 adrenergic 
receptor antagonists only at the spinal level. The supra-
spinal system may also play an important role, and the two 
systems may interact with each other in the nociception. 
Second, there are numerous subtypes of 5-HT, α1 and α2 
adrenergic  receptors,  and  the  analgesic  mechanism  of 
COX-2 inhibitors might be associated with specific sub-
types of those receptors. Therefore, further research will 
be needed to establish the properties of supraspinal path-
ways in relation to serotonergic and noradrenergic trans-
mission, and the differential roles of their receptor sub-
types in CO X-2 inhibitor analgesia.184 Korean J Pain Vol. 24, No. 4, 2011
    In conclusion, intrathecal DUP-697, a selective CO X-2 
inhibitor,  effectively  relieved  inflammatory  pain  in  rats. 
The 5-HT and NE systems might not be involved in the 
analgesic activity of COX-2 inhibitors on the facilitated 
pain state as well as on acute pain in the rat spinal cord.
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